Nilotinib + LDE225

Phase 1Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Philadelphia Chromosome Positive Chronic Myelogenous Leukemia

Conditions

Philadelphia Chromosome Positive Chronic Myelogenous Leukemia

Trial Timeline

Jan 1, 2012 → Feb 1, 2014

NCT ID

NCT01456676

About Nilotinib + LDE225

Nilotinib + LDE225 is a phase 1 stage product being developed by Novartis for Philadelphia Chromosome Positive Chronic Myelogenous Leukemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01456676. Target conditions include Philadelphia Chromosome Positive Chronic Myelogenous Leukemia.

What happened to similar drugs?

2 of 8 similar drugs in Philadelphia Chromosome Positive Chronic Myelogenous Leukemia were approved

Approved (2) Terminated (1) Active (5)

❌NilotinibNovartisPhase 3

🔄NilotinibNovartisPhase 3

🔄Asciminib + NilotinibNovartisPhase 3

✅NilotinibNovartisApproved

🔄Imatinib + Nilotinib + Bosutinib + Dasatinib + AsciminibNovartisPhase 3

✅AsciminibNovartisApproved

🔄Blinatumomab + Blinatumomab + HyperCVADAmgenPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01456676	Phase 1	Completed	Jan 1, 2012	Feb 1, 2014	Philadelphia Chromosome Positive Chronic Myelogenous Leukemia

Competing Products

20 competing products in Philadelphia Chromosome Positive Chronic Myelogenous Leukemia

See all competitors

Product	Company	Stage	Hype Score
Imatinib Mesylate	Novartis	Phase 2	35
Nilotinib	Novartis	Phase 3	32
Nilotinib	Novartis	Phase 3	40
STI571 400 mg + STI571 600 mg	Novartis	Phase 2	35
Induction Phase + Re-Induction Phase + Post-Remission + Maintenance	Novartis	Phase 2	42
nilotinib	Novartis	Phase 2	35
Asciminib + Nilotinib	Novartis	Phase 3	44
imatinib mesylate	Novartis	Phase 2	35
Blinatumomab + Asciminib	Novartis	Phase 1/2	39
Asciminib	Novartis	Phase 1	36
Asciminib Pediatric formulation group + Asciminib Adult formulation group	Novartis	Phase 1/2	39
Nilotinib	Novartis	Approved	43
Imatinib + Nilotinib + Bosutinib + Dasatinib + Asciminib	Novartis	Phase 3	44
Asciminib	Novartis	Approved	47
Blinatumomab	Amgen	Phase 2	35
Treatment with blinatumomab given subcutaneously.	Amgen	Phase 2	42
Blinatumomab + Blinatumomab + HyperCVAD	Amgen	Phase 3	47
Blinatumomab + Low-intensity chemotherapy regimen + SOC chemotherapy regimen	Amgen	Phase 3	47
Bosutinib	Pfizer	Phase 1/2	36
Bosutinib + Bosutinib	Pfizer	Phase 1	29